Roche: raises FY targets

(CercleFinance.com) - At its trading update, Roche has further raised its FY 2019 forecasts, now looking for high single-digit sales growth at constant exchange rates.


Over the first nine months of 2019, the Swiss pharmaceutical group's sales increased by 10% at constant exchange rates and by 9% as reported to 46.1 billion Swiss francs, thanks to the launch of new products.

In local currencies, the pharma division's sales grew by 12%, driven by Ocrevus, Hemlibra, Tecentriq and Perjeta in particular, and that of the diagnostic division (4%), mainly thanks to its portfolio of immunodiagnostic tests.


Copyright (c) 2019 CercleFinance.com. All rights reserved.